178 results about "Peptide complex" patented technology

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

Provided are a T-cell receptor (TCR) and the use thereof, wherein the TCR contains an α chain containing a variable region and / or a β chain containing a variable region. The TCR is capable of specifically recognizing an A1101-restricted KRASG12V mutation and an A1101-restricted KRASG12D mutation. A T cell transducing the TCR (TCR-T) can bind to an antigen short peptide-HLA-A1101 complex, and can be used for treating malignant tumors carrying the KRASG12V mutation and KRASG12D mutation.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The invention relates to the technical field of food, in particular to geobacillus stearothermophilus cKM-Geo, application of the geobacillus stearothermophilus cKM-Geo, a shrimp shell oligosaccharide peptide compound and a preparation method of the shrimp shell oligosaccharide peptide compound. The invention provides geobacillus stearothermophilus cKM-Geo, the strain can grow in an oxygen-free environment, ventilation is not needed in the process, and proteolytic enzyme, cellulase, lipase and chitin deacetylase can be highly secreted and expressed; the invention further provides a preparation method for preparing the shrimp shell oligosaccharide peptide by utilizing geobacillus stearothermophilus cKM-Geo fermentation coupling steam explosion treatment, chitin and protein in the shrimp shell are converted into water-soluble oligopeptide and oligosaccharides, the water-soluble oligopeptide and oligosaccharides are separated from calcium carbonate in the shrimp shell, acid and alkali do not need to be used, in the process, waste water is little, pollution is little, and the method is suitable for industrial production. The resource utilization rate is high.

The peptide complex of the present invention promotes the expression of the SIRT1 gene, referred to as a longevity gene, promotes the expression of the FGF21 gene, and increases the phosphorylation of AMPK. In addition, the peptide complex of the present invention exhibits an anti-inflammatory effect. Therefore, the peptide complex of the present invention inhibits aging, promotes the expression of the longevity gene SIRT1 gene, and can be used for treating or preventing diseases associated with SIRT1.

The invention relates to tumor-targeted trimeric polypeptides based on the homotrimerization region from collagen XV or XVIII and which contain domains capable of specifically binding to and activating receptors of the TNFR family of costimulatory receptors as well as to the uses thereof in the treatment of cancer.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

The present disclosure provides a polypeptide complex comprising a target binding polypeptide that binds to a molecule on a target cell or a molecule in an extracellular matrix (ECM); and small latent complexes comprising in particular a dimer latent related polypeptide (LAP) or a fragment or derivative thereof, and a dimer mature transforming growth factor beta (TGF beta) family polypeptide or a fragment or derivative thereof. Polypeptides (e.g., fusion polypeptides), and related polynucleotides, vectors, cells, and pharmaceutical compositions are also provided. Also provided are methods of treating subjects using, for example, these polypeptide complexes and / or these fusion polypeptides or pharmaceutical compositions thereof.

The invention relates in one aspect to a computer-implemented method for predicting the binding of at least one protein of interest, preferably at least one receptor, antibody, antibody fragment or equivalents thereof, or DARPin, to a peptide of interest, comprising a. providing sequence and / or structural data of at least one reference peptide, optionally providing sequence and / or structural data of at least one HLA molecule and / or of at least one HLA-peptide complex (pHLA), and / or the at least one reference peptide presented within a pHLA complex, b. providing binding data, preferably comprising the dissociation constant (KD), of the at least one reference peptide and / or the at least one reference peptide presented within a HLA-peptide complex (pHLA) with at least one protein of interest, c. training a machine learning (ML)-based model or artificial intelligence (AI) based on the data provided in a. and the binding data provided in b., d. providing sequence and / or structural data of at least one peptide of interest, e. employing the machine learning (ML)- based model or artificial intelligence (AI) trained in c. to predict the binding or interaction properties of the at least one peptide of interest, preferably when presented within a pHLA complex, to the at least one protein of interest.

The invention relates to an SR-B1 targeted polypeptide compound and application thereof in preparation of antitumor drugs and immunotherapy sensitizers, and belongs to the technical field of biological drug manufacturing. In order to solve the problems that an existing PD-L1 inhibitor is single in action mechanism and immune system dysfunction is easily caused, the invention provides an SR-B1 targeted polypeptide compound which is composed of SR-B1 targeted polypeptide and Resiquimod. The SR-B1 targeting polypeptide comprises an SR-B1 targeting peptide fragment, a self-assembly peptide fragment and a hydrophobic molecule which are connected in sequence. The SR-B1 targeting polypeptide can recognize overexpressed SR-B1 in tumor cells, block cholesterol uptake, inhibit tumor progression and inhibit expression of PD-L1 at the same time. The polypeptide compound accurately delivers Resiquimod to a tumor site, anti-tumor immune response is activated, and sensitivity of tumor immunotherapy is greatly enhanced through combination of cholesterol metabolism regulation and immunotherapy.

A multispecific polypeptide complex, an isolated polynucleotide encoding the same, a pharmaceutical composition comprising the same, and uses thereof.

The invention discloses a preparation method of a red rice bran protein peptide compound with antioxidant and hypoglycemic effects. According to the method, red rice bran protein is extracted through an alkali-solution and acid-isolation method; hydrolyzing the red rice bran protein with alkaline protease to obtain a red rice bran protein hydrolysate; the red rice bran protein hydrolysate prepared by the invention has the functional characteristics of excellent emulsibility, foamability and oil absorbency, and has excellent antioxidant and hypoglycemic functional activities after being subjected to in-vitro simulated gastrointestinal digestion. The red rice bran protein hydrolysate can be used in plant-based food and dairy product substitutes and functional food with a hypoglycemic effect.

Disclosed herein are compositions and uses of tumor activated antibodies targeting EGFR and effector cell antigens. In particular, the present application provides isolated recombinant polypeptide complexes that comprise binding domains that selectively bind to an effector cell antigen and EGFR, in which one or more of the binding domains is selectively activated in the tumor microenvironment and the isolated polypeptide or polypeptide complex comprises a half-life extending molecule.

Methods of analyzing the presence or absence of immune cells capable of binding to an antigen peptide in a sample from one or more individuals are provided. Also provided are methods of detecting or treating cancer or a tumor, a pathogen infection, or an autoimmune disease. A display moiety is provided having particles associated with a plurality of MHC-peptide complexes, where at least two MHC-peptide complexes are different. Also provided are bait compositions having a plurality of display portions and methods of analyzing immune cells by using the display portions or bait compositions as screening tools.

This invention provides a sodium hyaluronate gel complex for wound repair and its preparation process, belonging to the field of gel complex preparation technology. The preparation process includes the following steps: preparation of a Poria cocos polysaccharide-antimicrobial peptide complex; preparation of catechol-grafted modified gelatin; preparation of oxidized sodium alginate; preparation of a sodium alginate complex; and preparation of a sodium hyaluronate gel complex. This invention prepares a sodium alginate complex with double dynamic bond crosslinking by side-linking catechol groups to gelatin, through the coordination between ferric ions and catechol groups, and the Schiff base reaction between the amino groups on gelatin and the aldehyde groups on oxidized sodium alginate. Furthermore, the sodium alginate complex is doped with the Poria cocos polysaccharide-antimicrobial peptide complex. The resulting sodium hyaluronate gel complex, prepared by compounding with thiolated sodium hyaluronate, exhibits good biocompatibility, high antibacterial activity, and significantly promotes wound healing.

The present disclosure relates to methods of treating a disease or disorder comprising administering activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) to subjects in need thereof.

This peptide includes an amino acid sequence represented by formula A1 or an amino acid sequence in which one or more amino acid residues in the amino acid sequence represented by formula A1 have been substituted, deleted, added, or inserted. A1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15

The present invention relates to a supramolecular peptide complex comprising several peptide oligomerisation domains capable of forming multivalent complexes, bonded to at least one antigen-binding molecule and to at least one chelating group binding at least one metal cation of a heavy metal (M) having an oxidation state (M2+, M3+, M4+).

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of HPV associated disease or cancer.

The invention relates to a method for the generation of a TCR in a rodent, method comprising delivering an antigen presenting cell (APC) expressing an MHC-peptide complex to the rodent, wherein the MHC component of the MHC peptide is not expressed and generating T-cells to the MHC-peptide complex in the rodent. The method further comprises isolating or purifying the T-cell from the rodent. The MHC component is either allogenic or xenogenic and the MHC expressed in the rodent is a human HLA, such as HLA-A*02:01, HLA-A*11:01, HLA-A*03:01 or HLA-A*24:02. The rodent genome encodes a fully human TCR. The peptide is from a human antigen associated with disease, such as a tumour associated antigen. The rodent genome comprises human CD8 or chimeric CD8. The TCR sequence has been modified by up to 3 amino acids from that identified in the rodent. Also disclosed is a method for generating a TCR in a mouse, identifying the nucleic acid encoding the TCR and then mutating the sequence. The TCR is expressed in the form of a larger molecule. The APC is a synthetic antigen presenting cell.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The invention relates to a bicyclic peptide complex comprising a peptide construct, said construct comprising (i) a polypeptide with free terminus (N or C); (ii) optionally, a nucleic acid encoding the polypeptide; (iii) a twofold-symmetric linker (TSL) compound attached to said polypeptide where the linker is attached to the terminus of polypeptide via a covalent bond and to at least two discrete side chains of the peptide. The invention also relates to libraries, and to methods for making complexes and to methods of screening using the same.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) that bind to HIV proteins and have certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes in HIV.

The present application relates to a preparation method of sea cucumber egg-derived peptide complex and application thereof.The preparation method of sea cucumber egg-derived peptide complex comprises the following steps: sea cucumber egg powder is subjected to synchronous enzymolysis by using alkaline protease and trypsin.Further separation is carried out through ultrafiltration, dextran gel chromatography and high performance liquid chromatography, sea cucumber egg-derived active peptides are obtained by using liquid chromatography-mass spectrometry technology, computer-aided screening technology and in-vitro verification, and the amino acid sequence of the sea cucumber egg-derived active peptides comprises one or several of WGN, WIGG and GFPVG.The sea cucumber egg-derived peptide complex and the sea cucumber egg-derived active peptides provided by the present application both have double activities of antioxidant and tyrosinase inhibition, can reduce melanin content, and have the advantages of good water solubility, good safety and the like.

The invention belongs to the technical field of cosmetics, and particularly relates to an anti-aging cell metabolism accelerating cosmetic and a preparation method thereof, and the technical scheme is that the anti-aging cell metabolism accelerating cosmetic comprises the following components: 0.0001%-0.005% of a cell growth factor compound, 0.0001%-0.003% of a small molecule peptide compound, 0.1%-5% of a plant stem cell extract, 1%-10% of grease, and the balance of water. 1%-10% of a surfactant, 1%-15% of a humectant, 0.1%-1% of an antioxidant, 0.1%-3% of a pH regulator, 0.05%-0.2% of a preservative and the balance of deionized water; epidermal and dermal layer cell proliferation is promoted through the cell growth factor, cell metabolism is regulated and controlled and collagen synthesis is promoted through the small molecule peptide, the plant stem cell extract is rich in polyphenol active ingredients and can activate the activity of skin endogenous stem cells, and the three components have a synergistic effect through different action pathways; the metabolism rate of skin cells and the anti-aging effect are obviously improved.

Methods of detecting the presence and quantity of anti-BSEP antibodies in a biological sample from a subject include contacting the biological sample with one or more BSEP peptides to form an antibody-BSEP peptide complex, and detecting the amount of the antibody-BSEP peptide complex in the biological sample. The one or more BSEP peptides may include one or more of a full length BSEP peptide (SEQ ID NO:1), and / or one or more epitopes of BSEP.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

The application provides a simple and efficient TCR-mimic antibody preparation method, and a TCR-mimic antibody for gp100 / HLA-A2 is obtained by screening by using the method. The TCR-mimic antibody provided by the application can recognize a MHC-tumor antigen peptide complex with high specificity and high affinity, and has the potential to be developed as a tumor antibody drug.